B. Riley Securities initiated coverage on Radiance Medical with a new price target
$RADX
B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $15.00 | Buy | B. Riley Securities |
DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, announced today that it has achieved a key milestone in its ongoing clinical development program for its clinical-stage radiotherapeutic asset, 177Lu-RAD204, as the Data and Safety Monitoring Committee (DSMC) has approved to proceed to the next dose in its Phase 1 clinical
SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at [email protected]. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform o
Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm's commitment to developing transformative oncology radiopharmaceuticals SYDNEY, April 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the dosing of the first patient in its U.S. Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis. The U.S. multicenter, open-label, single arm Phase 2b
6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
SCHEDULE 13G - Radiopharm Theranostics Ltd (0001949257) (Subject)
6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)
B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00